Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers

Transplant Rejection Clinical Trial

Official title:
An Open-label, Single-sequence Study of the Effect of Belatacept on the Pharmacokinetics of Caffeine, Losartan, Omeprazole, Dextromethorphan, and Midazolam Administered as "Inje Cocktail" in Healthy Subjects

Status Completed

Clinical Trial Summary

The purpose of this study is to determine the effects of belatacept on the pharmacokinetics of caffeine, losartan, omeprazole, dextromethorphan and midazolam

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

Transplant Rejection

Clinical Trial Details

NCT number	NCT01766050
Study type	Interventional
Source	Bristol-Myers Squibb
Contact
Status	Completed
Phase	Phase 4
Start date	January 2013
Completion date	April 2013

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04615221` - Immunological Mechanisms of Rejection in Uterine Transplantation	N/A
Recruiting	`NCT03984747` - Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection
Completed	`NCT04046549` - A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant	Phase 2
Completed	`NCT01338779` - Study of Tolerant Kidney Transplant Recipients	N/A
Recruiting	`NCT05156710` - BIVV020 (SAR445088) n Prevention and Treatment of Antibody-mediated Rejection (AMR)	Phase 2
Completed	`NCT03582436` - Rejection Diagnosis in Kidney Transplants Patients
Completed	`NCT01236378` - Study To Evaluate Pharmacokinetics Of Sirolimus In Stable Renal Transplant Recipients	Phase 1